SVB Leerink Maintains Market Perform on bluebird bio, Lowers Price Target to $8
SVB Leerink analyst Mani Foroohar maintains bluebird bio (NASDAQ:BLUE) with a Market Perform and lowers the price target from $10 to $8.
Bluebird Bio Joins Layoff Band Wagon As Gene Therapy Biotech Cuts Staff To Reduce Costs
Bluebird Bio Inc (NASDAQ:BLUE) is laying off about 30% of its workforce before the FDA decides the fate of two of…
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products.
76 Biggest Movers From Yesterday
Gainers
Houston American Energy Corp. (NYSE: HUSA) surged 494.7% to close at $11.30 on Monday amid continued momentum and an increase in the price of oil.
Mid-Day Market Update: Nasdaq Drops 250 Points; Bed Bath & Beyond Shares Surge
U.S. stocks traded lower midway through trading, with the Nasdaq dropping 250 points on Monday. The Secretary of State Antony Blinken said on Sunday that the United States and its allies are considering a ban on Russian oil and natural gas imports.
46 Stocks Moving In Monday’s Mid-Day Session
Gainers
Houston American Energy Corp. (NYSE: HUSA) jumped 137.4% to $4.5150 amid continued momentum and an increase in the price of oil.
Morgan Stanley Maintains Underweight on bluebird bio, Lowers Price Target to $5
Morgan Stanley maintains bluebird bio (NASDAQ:BLUE) with a Underweight and lowers the price target from $6 to $5.
